5/24/23

New Access Accelerated Global Collective Report Charts Path Forward in Fight Against Noncommunicable Diseases

GENEVE, CH, May 24, 2023 – (亞太商訊 via SEAPRWire.com) – Access Accelerated, a pioneering collective of leading biopharmaceutical and life science companies dedicated to confronting the growing global noncommunicable disease (NCD) crisis, announced the release of a six-year report: Key Lessons in Advancing Access to NCD Care: Collaboration, Connectivity, Community.

This milestone report highlights the initiative’s outcomes, impact, and collective learnings between 2017 and 2022 and serves as a retrospective, a showcase for the initiative’s success stories and challenges, and a much-needed vision for the future.

Michael Fredrich, Lead Access to Medicine Non-Communicable Diseases at Bayer Pharmaceuticals and Chair of the Access Accelerated Board, commented, “With the 2030 deadline for the UN Sustainable Development Goals approaching fast, which include Universal Health Coverage, it’s more important than ever that we make the most out of our resources and approach this fight strategically. This report gives us the opportunity to critically evaluate our past and use key learnings for the future. It is essential that we share insights and learn from our collective efforts. Much work lies ahead, but this report serves as a valuable foundation for effectively addressing NCDs.”

This initiative’s impact has already been felt widely. Access Accelerated and its strategic partners – the City Cancer Challenge Foundation, NCD Alliance, PATH, the World Bank and the World Heart Federation – have helped improve access to NCD screening, diagnosis, and treatment around the world, reaching over 700 million people through 54 partner projects in 37 countries and catalyzing $US1.6 billion in investment in 2022 alone. By the end of phase 2 (2020-2022), this number totalled $US3.7 billion. In the same period, Access Accelerated partner projects contributed to policy change in 35 countries and 13 projects were scaled to national level, moving away from pilot phase to locally embedded projects.

Six years since its founding, the initiative has accumulated a wealth of hard-won knowledge and experience. The report highlights those learnings, including the crucial role of open, transparent communication in measuring intangible impact of partnerships, the ways flexible long-term funding can open the way for locally embedded solutions, and why community- and patient-centric approaches are essential to sustainability. By capturing impacts beyond hard numbers, the report demonstrates the importance of local engagement, trust, and social capital in improving NCD outcomes over time.

According to Dr. Juan Pablo Uribe, World Bank’s Global Director for Health, Nutrition & Population and Director of the Global Financing Facility, the report demonstrates the importance of rigorous monitoring and reporting. “Learning from our successes and challenges is absolutely necessary if we are going to shape more efficient and effective initiatives that can respond to the growing NCD burden on countries around the world. That’s why we’re excited to have the insights offered by this report to inform future initiatives and are grateful to the partnership with Access Accelerated which has led to meaningful action in creating sustainable change.”

Visit www.accessaccelerated.org to download the report.

About Access Accelerated

Founded in 2017, Access Accelerated is an unprecedented industry-led collective of life science companies united by the belief that no person should die from a preventable and treatable disease. Through the power of collaboration and a proven framework for cooperation, Access Accelerated brings together stakeholders across the private, public and social sectors, including implementers, decision-makers and financiers, in a shared mission of advancing action against the escalating challenge of NCDs in low- and middle-income countries and underserved communities.

Contact Information
Thuy Khuc-Bilon
Communications Manager
info@accessaccelerated.org
+41 79 473 0341

Copyright 2023 亞太商訊. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/new-access-accelerated-global-collective-report-charts-path-forward-in-fight-against-noncommunicable-diseases/

Revolutionizing HR through Technology: Explore the HR Tech Strategy Meeting Philippines 2023

MANILA, May 24, 2023 – (ACN Newswire via SEAPRWire.com) – In today’s business landscape, organizations widely recognize the crucial role of technology in HR, enabling data-driven decision-making, enhancing employee experiences, and fostering strategic HR management.

In line with this, rockbird media’s HR Leaders’ theme of events proudly presents the highly anticipated “HR Tech Strategy Meeting Philippines 2023: Digital HR for a Transformed Workforce.” This exclusive event will take place on June 28, 2023, at Hilton Manila, Philippines.

Bringing together C-level executives, directors, and top HR leaders from the country, this gathering aims to explore advanced HR techniques for building a future-ready workforce. Attendees will have a valuable opportunity to network and establish connections with leading industry experts and well-renowned HR professionals from diverse sectors.

The event will showcase a thoughtfully curated lineup of speakers who will delve into a wide range of HR Tech topics including HR automation, streamlining recruitment and onboarding processes, employer branding, collaboration tools, digital well-being, and more. These topics will be explored in detail through interactive breakout sessions, insightful keynote presentations, and dynamic panel discussions.

The HR Tech Strategy Meeting Philippines 2023 promises to be a pivotal event for HR leaders seeking to stay at the forefront of industry advancements. It will foster an environment conducive to knowledge-sharing, idea exchange, and collaboration, equipping participants with the necessary tools and insights to navigate the rapidly evolving HR landscape.

To learn more about the event and secure your registration, please visit https://hrleaders.rockbirdmedia.com/

About rockbird media

Rockbird media is an international business media company that produces B2B events and offers business solutions.

Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow. For more information, visit https://rockbirdmedia.com.

Media contact:
Imee Rose Mariano
im.mariano@rockbirdmedia.com

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/revolutionizing-hr-through-technology-explore-the-hr-tech-strategy-meeting-philippines-2023/

5/23/23

OCTO, new FinOps solution from Alphaus, to help businesses maximize ROI on their cloud usage

KUALA LUMPUR, May 24, 2023 – (ACN Newswire via SEAPRWire.com) – Alphaus Inc. (https://alphaus.cloud/en/), the market leader in cloud financial management (CFM) solutions in Japan with a growing regional presence in Southeast Asia, is extending its suite of SaaS solutions to cater to SMEs and large enterprises running on cloud infrastructure.

Having successfully delivered huge cost savings to companies in Japan and Southeast Asia through its proven solutions for managed service providers (MSP), the company is now globally introducing OCTO, a SaaS-based FinOps platform for any business that uses cloud infrastructure for its operations. Beyond cost savings, OCTO enables finance, FinOps and DevOps teams to work together effectively to achieve the best outcomes for the business. Moreover, OCTO integrates effectively with a multitude of third-party solutions, acting as the connecting hub that brings them all together. This seamless integration enhances user experience, solidifying OCTO as an essential tool for end-users.

Companies interested in minimizing wasted cloud spend, saving costs and maximizing their ROI are now invited to sign up for the waitlist to experience the many benefits of OCTO.

OCTO enables cost aggregation by account, service, or tags with centralized account management for AWS, Azure, and Google Cloud Platform (GCP). Smart visualization through project-specific dashboards provides a clear view and understanding of all cloud costs. With advanced tag management, OCTO then intelligently distributes project costs and allocates credits and savings through its optimization capabilities. It helps businesses with a comprehensive cost optimization cycle covering numerous daily operations and enabling auto-pilot cost optimization, together with detailed metrics for gauging success of plans and actions.

“Due to the growing complexity of cloud technologies, most businesses find it a significant challenge to track cloud usage and associated costs across the organization. This lack of clear visibility and understanding of cloud costs negates the potential benefits and savings for companies by using the cloud,” said Hajime Hirose, CEO of Alphaus. “We aim to solve this problem at scale with a versatile, comprehensive, and user-centric solution like OCTO, and help any business- whether it is a SME or a large-enterprise- to fully realize the benefits of using the cloud. Beyond understanding cloud spend, we want to empower businesses to seamlessly manage and optimize that spend with appropriate allocation, generate savings, and make a tangible impact on their bottom line.”

Don’t miss out on the opportunity to save on cloud costs and maximize your ROI. Sign up for the waitlist today and be among the first to experience the many benefits of OCTO. Visit: https://lp.alphaus.cloud/

About Alphaus Inc.

Alphaus (https://alphaus.cloud/en/), a VC-backed tech start-up on a mission to simplify cloud computing for everyone, specializes in Cloud Financial Management (CFM) solutions. The company enables cloud services partners and other businesses to understand, manage and optimize complicated cloud spend, billings and resource allocation for maximizing ROI on their investments in the cloud. Alphaus provides a suite of Software-as-a-Service (SaaS) solutions for multi-cloud management supporting AWS, Microsoft Azure, and Google Cloud.

Founded in 2015, Alphaus Inc. is backed by reputed investors like DNX Ventures, NTT DoCoMo Ventures, Mitsubishi UFJ Capital, Archetype Ventures, Accord Ventures, and 500 Global. The company’s roster of clients includes NTT Data, Nomura Research Institute (NRI), and ISI-Dentsu. Headquartered in Japan, Alphaus has a rapidly growing Global Delivery Centre and Regional Headquarter in Kuala Lumpur Malaysia to support its rapid expansion in the Asia Pacific and Oceania regions.

Media Contact:
Hajime Hirose, CEO
Tel: +81.70.3173.7354
E-mail: Hajime.hirose@alphaus.cloud

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/octo-new-finops-solution-from-alphaus-to-help-businesses-maximize-roi-on-their-cloud-usage/

Talon Esports, IMG, Warner Music Singapore, MOONTON Games amongst first wave of ESI Singapore 2023 speakers

ESI Singapore tickets are still available here.

Singapore, May 24, 2023 – (ACN Newswire via SEAPRWire.com) – The leading B2B esports events and media company, Esports Insider, and Singapore-based esports marketing agency, Redd+E, are proud to announce the first wave of esteemed speakers for the upcoming ESI Singapore esports industry conference. Set to take place on 20-21 June at the Asian Civilisations Museum, ESI Singapore is set to provide attendees with valuable insights, networking opportunities, and thought-provoking discussions on the future of esports and beyond.


Among the prominent speakers who will grace the stage at ESI Singapore 2023 are:

  • Joe Jenkins – Head of Esports, IMG Media
  • Timo Krueger – Commercial Director Esports & Gaming, Nielsen
  • Gerald Ang – Managing Director, Warner Music Singapore
  • Ray Ng – Head of Esports Ecosystem, MOONTON Games
  • Jarrold Tham – Co-Founder, Talon Esports
  • Gary Ongko Putera – CEO, BOOM Esports
  • Debora Imanuella – Senior Vice President, UniPin Global
  • Oh Teck Wee – CFO, Affyn
  • Charlie Hanley-Nickolls – Chief Product Officer, GRID
  • Benedikt Becker – Director of Sales and Marketing, Shikenso Analytics
  • Gerald Solomon – Founder & Executive Director, NASEF
  • Mervyn Lai – Managing Director, Playbook Academy
  • Abdiqani Ahmed – Founder, Lionscreed Esports

These industry leaders, along with many more yet to be announced, will share their expertise, discuss emerging trends, and provide valuable insights into the ever-evolving world of esports, video games and Web3.

Sam Cooke, Managing Director of Esports Insider commented, “We are thrilled to unveil such an exceptional lineup of speakers for ESI Singapore 2023. Each speaker brings a unique perspective and extensive experience in their respective fields, ensuring that attendees will gain valuable knowledge and insights.”

ESI Singapore 2023 will offer a diverse range of topics across key tracks such as Commercialisation, Revenues & Investment; Web3; Community and Education. Attendees can look forward to engaging panel discussions and unparalleled networking opportunities, including an evening social at the exclusive ParkRoyal Collection Pickering hotel.

Co-host of #ESISG – Redd+E’s Managing Director & Co-founder, Yip Ren Kai added, “The esports and gaming community in APAC is rapidly evolving. With a whole new slate of partners such as Warner Music, Krafton and MOONTON Games, the developers of highly popular PUBG and Mobile Legends Bang Bang (MLBB) respectively, we are excited for expanding the range of topics that we can cover in esports – expanding our horizons to include explorations into new areas such as music and education.”

The event is supported by Singapore Exhibition & Convention Bureau and its partners including: Main Stage Sponsor GRID; Official AV Partner The Gym Esportscentre, Travel Partner Westpoint Transit; Event Partner Shikenso Analytics, Official Hotel Partner PARKROYAL COLLECTION Pickering, and media partners ACN Newswire, 80LV and Mailman Group. ESI Singapore is set to welcome over 400 attendees, with over 40+ speakers across more than 10 live sessions.

Full Passes, group and student tickets are still available here. To register or to learn more about the event, please visit https://esportsinsider.com/esi-singapore-2023/ . For special hotel rate for #ESISG attendees at PARKROYAL COLLECTION Pickering, Singapore, please book here.

About Esports Insider

Based in London and founded in 2016, Esports Insider is an industry-focused esports news platform, B2B agency, media and events company.

ESI runs a world-leading and international esports industry news site, operates The Esports Journal magazine and has run more industry events than any other company globally, from London to Los Angeles. Other arms of the company include ESI Media, as well as ESI Connect, its agency arm which offers services across Brokerage, Consultancy and Campaign Activation.

Website // Twitter // Facebook // Linkedin // Instagram // YouTube // Discord

About Redd+E

Redd+E, through its parent company Reddentes Sports, is a marketing agency that delivers smart and impactful solutions in the areas of esports.

Our services include media rights consulting, commercialisation development, event consulting, project management, organisational consultancy for sports associations, athlete management and marketing consultancy. Our goal is to provide services and value to transform organisations, businesses and communities by achieving their objectives through esports.

Facebook // Linkedin // Instagram // Website

Contacts:
General Enquiries:-info@esportsinsider.com
Event Enquiries: events@esportsinsider.com
PRs & pitches:- news@esportsinsider.com

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/talon-esports-img-warner-music-singapore-moonton-games-amongst-first-wave-of-esi-singapore-2023-speakers/

BBS.NYC, the WorldWide AI+WEB3.0 Summit to Be Held in New York on June 1st

New York, NY, May 23, 2023 – (SEAPRWire) – BBS.NYC the worldwide AI+WEB3.0 summit, will be held on 1st June in New York City. BBS.NYC is a global AI+WEB3.0 summit held twice a year in different cities of the world. The summit aims to bring together global AI+WEB3.0 leaders, scientists, project developers, investors, and government authorities to explore cutting-edge Web3.0 technologies and investment hotspots.

The first summit of 2023, will kick off on June 1st at The Altman Building, New York. It is expected to have around 800 participants from all over the world.

This year, the topics covered include zero-knowledge proof (zk), digital wallets, distributed science (DeSci), DeFi, SocialFi, cryptocurrency payments and the combination of Web3 and AI.

Numbers of government leaders have also been invited to participate the summit, mainly from Caribbean countries.

Top Venture Capital firms, scholars, project developers, and top investors in the fields of AI, blockchain and artificial intelligence will share their views and insight in their speeches during the summit.

Panel discussions will also be held, and the guests can exchange their views with the speakers.

Apart from the summit, BBS.NYC will also hold a Demo Day with DeSci NYC and several venture capital firms on May 31st at the Altman Building, New York.

The participants include dozens of well-known blockchain projects such as OKX, BitMart, Certix, Univest Securities, Dcoreum, Alchemy Pay, Chainge Games, GD Culture Group, Transwap, PaymentAsia, DemonWar and Followin.

Industry leaders and investors are invited to participate in the roadshow. Participants will have the opportunity to showcase their projects, exchange ideas and insights with industry leaders, and establish connections with peers from around the world.

Social Links

Twitter: https://twitter.com/BBSNYC2023

Media Contact

Brand: BBS.NYC

Contact: Grace, Project Manager

Website: https://www.bbs.nyc/

SOURCE: BBS.NYC

The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com

Sectors: Top Story, Daily News

SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)



source https://netdace.com/top-story/bbs-nyc-the-worldwide-aiweb3-0-summit-to-be-held-in-new-york-on-june-1st/

Hitachi Vantara Secures the State of Arizona’s Critical Water Resources with Modern Data Management and Analytics

SANTA CLARA, CA, May 23, 2023 – (JCN Newswire via SEAPRWire.com) – Hitachi Vantara, the modern infrastructure, data management and digital solutions subsidiary of Hitachi, Ltd. (TSE: 6501), today announced that the Arizona Department of Water Resources has selected Hitachi Vantara’s Pentaho Data Catalog to centralize, categorize, sort and analyze trusted data across 330,000 distributed water resources in the state. The solution is part of the State of Arizona’s efforts to bolster sustainability and resource management and secure the future of water for the Grand Canyon State’s 7 million residents amid the broader water supply challenges facing the Southwest.

To effectively manage Arizona’s water supply, the Department of Water Resources collects, stores and conducts analysis on reported water uses of nearly 6 trillion gallons per year across thousands of wells and surface water sources. By analyzing data against records of geolocation coordinates, depth to water and uses, the agency is better equipped to establish the adjudication of water rights with trusted, accurate data. Without a metadata repository, staff had difficulty finding important data sets, leading the organization to focus on automating data quality to support its staff and resources. Considering the ongoing drought and reduced water supply from the Colorado River, having a data-driven approach to water management is absolutely crucial.

Hitachi Vantara’s Pentaho Data Catalog provides intelligent data discovery, classification and visualization of relationships, allowing the department to use machine learning and automation to recognize different structured data types, including geospatial data. Hitachi Vantara’s technology enabled the Arizona Department of Water Resources to employ machine learning algorithms to sample legacy records at scale, generate accompanying metadata and categorize that data by key relationships. The Hitachi Vantara Pentaho Data Catalog makes all that visible via an easy-to-use, integrated and centralized dashboard. As a result, the department can now understand, integrate and analyze its unique and critical data sets to meet the needs of Arizona’s water users, planners and decision makers.

“We’re excited about Hitachi Vantara’s Data Catalog. All we need to do is type in ‘well,’ and this Hitachi Vantara solution delivers an accurate, comprehensive report of hundreds of instances of that data element in our transactional databases, data warehouse and document management system, and spatial data is ready for export. It is saving us so much time,” said Lisa Williams, manager, Office of Enterprise Data Management at the State of Arizona’s Department of Water Resources. “Having a centralized metadata repository enables our staff and consultants to quickly understand that data, and its complete lineage so we know the provenance of the data. It also frees up time for our people to analyze and manage groundwater conditions.”

“Helping the planet and improving business operations go hand-in-hand. In both cases, data is the underlying key to success,” said Maggie Laird, head of Lumada Software business and corporate sustainability, Hitachi Vantara. “With natural water supplies at their lowest levels in decades, having an accurate view of data helps the State of Arizona better protect, conserve and enhance water supplies in a bold, thoughtful and innovative manner.”

Hitachi Vantara helps customers achieve sustainability benchmarks by harnessing data for improved insights and more efficient operations, including helping South African Information and Communications Technology company Gijima reduce energy consumption by more than 60%, enabling German manufacturer Blechwarenfabrik Limburg GmbH to save more than half a million euros in energy costs, and empowering Australia’s Golden Grove Nursery to improve its irrigation practices by 30%.

Additional Resources
– Case Study: The State of Arizona Manages Water Resources More Sustainably With
Hitachi Vantara’s Pentaho Data Catalog (bit.ly/45qgffF)
– Webcast: State of Arizona Accelerates Trusted Data Discovery with Lumada Data Catalog (bit.ly/45mFzmT)
– Hitachi Vantara Sustainability Solutions (www.hitachivantara.com/en-us/solutions/sustainability.html)
– Blog: DataOps and the Sustainable Data Center (www.hitachivantara.com/blog/dataops-sustainable-data-center/)
– Pentaho Data Catalog Overview Video (www.hitachivantara.com/en-us/resources.html)
– Hitachi Vantara: Corporate Social Responsibility (www.hitachivantara.com/en-us/company/corporate-social-responsibility.html)

About Hitachi Vantara

Hitachi Vantara, a wholly-owned subsidiary of Hitachi Ltd., delivers the intelligent data platforms, infrastructure systems, and digital expertise that supports more than 80% of the Fortune 100. To learn how Hitachi Vantara turns businesses from data-rich to data-driven through agile digital processes, products, and experiences, visit www.hitachivantara.com.

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company’s website at www.hitachi.com.

Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/jcn-newswire/hitachi-vantara-secures-the-state-of-arizonas-critical-water-resources-with-modern-data-management-and-analytics/

致豐集團(1710.HK)新廠房落成啟用 座落粵港澳大灣區中心 高度數碼化生產線擴大產能 展示自有電動車充電解決方案Deltrix

EQS 新聞 via SEAPRWire.com / 2023-05-23 / 13:41 UTC+8

致豐工業電子集團有限公司
股份代號: 1710.HK

致豐集團新廠房落成啟用 座落粵港澳大灣區中心

高度數碼化生產線擴大產能 展示自有電動車充電解決方案Deltrix

 
 

 [香港 – 2023 年 5 月 23日] 致豐工業電子集團有限公司(“致豐集團”或“集團”,股份代號:1710)為香港領先的工業電子零件及產品製造及銷售企業,集團於5月18日為廣州南沙區東涌鎮的新廠房進行開幕儀式,並邀得東涌鎮黨委副書記兼鎮長伍進女士、黨委委員鄭艷雲女士、副鎮長梁杰銘先生擔任主禮嘉賓,聯同集團主席兼執行董事黃思齊先生、行政總裁關燦光先生、執行董事戴良林先生、執行董事Joe Mac Carthy先生及執行董事羅嘉祺先生於台上主持剪綵儀式,正式宣佈兩棟新廠房落成啟用。

 

新廠房共兩幢,面積達兩萬五千平方米,配置高度自動化及數碼化生產線,將進一步提高本集團大量生產高價值及重型產品系列的能力,加強集團的生產效率和擴大產能。新廠房毗鄰現有廠房,擴建後面積共達四萬六千七百平方米,並獲工業4.01i級的工業4.0成熟度認證證書,高度智能化的水平不容置疑。目前集團正積極研發自有電動車充電解決方案,隨著新廠房的啟用,致豐集團不但大幅提升產能,亦將加快促進現有電動汽車充電器產品的業務發展。

 

東涌鎮黨委副書記兼鎮長伍進女士致辭,熱烈祝賀致豐集團的新廠房落成投用。她形容公司作為國內電子工業行業領軍型企業,其技術水平、生產規模和產品品質一直走在同行業的前列。新廠房項目是南沙區首個村級工業園提質增效示範項目,更是納入了2019年廣州市產業園區提質增效試點項目,寄望集團充分利用新投產廠房擴大充電、節能設備等新興行業產能,與發展迅速的南沙共同成長。

 

集團主席兼執行董事黃思齊先生致辭中表示:「我看到集團的改變。今天我們加添了兩幢新廠房,配備現代化設備,產品加多了用自身品牌 Deltrix的電動車充電器,近百位嘉賓莅臨,包括鎮長伍進女士及其他政府官員、投資界、銀行界、基金、長期客户、供應商與及媒體等新舊朋友,濟濟一堂。我們全體員工將會全力以赴開展致豐新的一頁,冀望業務能夠再上一層楼。40年過去,趁此值得纪念的日子,希望同事們能夠享受致豐的這一刻。」

 

致豐集團執行董事羅嘉祺先生致辭,感謝客戶一直以來對集團的關心和支持。他強調,致豐集團對於南沙新區的未來非常有信心,在未來的日子裡,致豐將一如寄往地以決心繼續拓展業務,為地區的經濟發展作出集團應有的貢獻。

2023年為致豐集團創辦40年,意義重大。集團於2022財年收入達到9.78億港元,溢利約 4,540 萬港元,充分彰顯了致豐產品在市場上的廣泛認同

 

未來,集團將繼續提升廠房自動化水平及產能規模,培養優秀的團隊,開拓高端產品及優質的客戶群,進一步捕捉新經濟對創新產品的龐大需求,用業績去證明集團的實力和回饋各界的長久支持和信任

 

關於致豐集團

 

致豐集團為香港先進工業電子零件及產品製造及銷售企業,並為香港電子工業供應商中首間企業獲工業4.01i級的工業4.0成熟度認證證書,擁有近40年行業經驗。集團的主要產品包括:智能充電器、機電產品及開關電源等,廣泛應用於智慧城市系統、醫療保健及再生能源領域。集團並建立良好的聲譽,成為眾多國際知名品牌信賴的供應商。客戶主要來自歐美,部分來自東南亞及中國。其中,集團因應全球發展智慧經濟,於2017年起與合作夥伴研發自有電動車充電解決方案Deltrix,並在歐洲市場推出。                           
 

如欲查詢更多資訊,請聯絡:

 

投資者關係:

Clara Chan – 投資者關係經理

clarachan@triohk.com.hk

 

傳媒查詢:

DLK Advisory
pr@dlkadvisory.com

文件: 致豐集團新廠房落成啟用 座落粵港澳大灣區中心 高度數碼化生產線擴大產能 展示自有電動車充電解決方案Deltrix

2023-05-23 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。

瀏覽原文: https://ift.tt/sYKyTgj

fncls.ssp?fn=show_t_gif&application_id=1638863&application_name=news&site_id=todayir_html



source https://netdace.com/eqs-newswire/%e8%87%b4%e8%b1%90%e9%9b%86%e5%9c%981710-hk%e6%96%b0%e5%bb%a0%e6%88%bf%e8%90%bd%e6%88%90%e5%95%9f%e7%94%a8-%e5%ba%a7%e8%90%bd%e7%b2%b5%e6%b8%af%e6%be%b3%e5%a4%a7%e7%81%a3%e5%8d%80%e4%b8%ad%e5%bf%83/

5/22/23

PowerUP Asia 2023 Opens Tomorrow with Power Electronics Trends in Focus

TAIPEI, TW, May 23, 2023 – (ACN Newswire via SEAPRWire.com) – The inaugural PowerUP Asia, organized by AspenCore, publisher of EETimes Asia, EETimes India, and EDN Asia, opens tomorrow with the latest power electronics topics, including wide-band gap (WBG) devices such as gallium nitride (GaN) and silicon carbide (SiC), power semiconductors, and related technologies, in focus.

With the theme Spotlight on Asia’s Power Electronics Innovations, Trends, and Developments, PowerUP Asia is a three-day virtual conference and exhibition (May 24-26, 2023) highlighting the latest technology developments, challenges, and opportunities in the power electronics sector.

PowerUP Asia builds on the success of the established PowerUP Expo, a virtual conference and exhibition being held by Power Electronics News. Focusing on trends and innovations in this region, speakers include:

  • Francesco Muggeri, Vice President of Marketing & Applications, Power Discrete & Analog, APeC/China, STMicroelectronics, WBG Technologies Toward Sustainability
  • Alex Lidow, CEO and Co-Founder, Efficient Power Conversion (EPC), GaN Evolution – The Present and the Future
  • Stephen Coates, General Manager (Asia) and VP of Global Operation, GaN Systems, GaN is Pushing the Boundaries of Power Density and Efficiency
  • Jacky Wan, Vice President, Supplier Management & Engineering – APAC, Arrow Electronics, and Jason Khor, Senior Manager, Engineering, Arrow Electronics, Powering the Future: The Rise of Wide Bandgap Materials in Industrial, Automotive, and Renewable Energy Applications
  • Andrea Bricconi, Chief Commercial Officer, Cambridge GaN Devices, Powering Up the Future with GaN: Why and How GaN is Replacing Silicon in Power Conversion
  • Dr. Ravinder Pal Singh, Product Application Engineer, Infineon Technologies, Wide Bandgap Devices for a Greener Future
  • Daryl Wan, Regional Sales Director, India, ASEAN, ANZ, Analog Devices Inc., Power to Unleash Your Innovations
  • Mark Gerber, Sr. Director, Engineering & Technical Marketing, ASE Inc., Advanced Packaging: Enabling Greater Power Efficiency
  • Hyungmook Choi (Michael Choi), VP of Power Business Development, UTAC Group, Revolutionizing the Semiconductor Market: Preparing for Future Growth in Automotive, AI, and HPC with Innovative Package Development for SiC, GaN, and Silicon Devices
  • Gabriel Rojas, Application Engineer, Rohde & Schwarz, Best Practice on Probing with High Voltage Differential Probes
  • Alvin Tan, Senior Marketing Manager, NXP Semiconductors, NXP EVSE Solutions for the Future

Spotlight on WBG

The WBG market has experienced expansion and rising industrial acceptance. As technology advances, businesses are creating a wide range of products that offer advantages in a number of applications for the industrial, automotive, and consumer industries, among others. Devices such as GaN and SiC are supplying the market with the proper input by offering fresh solutions to the challenges that designers confront in an era where “efficiency” is the watchword.

At PowerUP Asia, a panel of industry experts from some of the leading companies focusing on GaN and SiC technologies will discuss the challenges that engineers currently face in a variety of application contexts, as well as the obstacles that still need to be removed for widespread adoption, to produce improved performance and lower costs that will benefit the industry as a whole.

With the theme “Recent Advances and Upcoming Challenges for Wide Bandgap Semiconductors,” the panel discussion will be moderated by Eng. Maurizio Di Paolo Emilio, Ph.D., Editor-in-Chief of Power Electronics News and EEWeb, will feature the following panelists:

  • Andrea Bricconi, CCO, Cambridge GaN Devices
  • Thierry Bouchet, CEO, Wise Integration
  • Stephen Coates, General Manager (Asia) and VP of Global Operation, GaN Systems Inc.
  • Amitava Das, Co-Founder & COO, Tagore Technology
  • Pete Losee, Director of Technology Development, Qorvo Inc.
  • Francesco Muggeri, Vice President of Marketing & Applications, Power Discrete & Analog, APeC/China, STMicroelectronics

For more information and to register, visit https://ve.eetasia.com/powerup2023.

About AspenCore

AspenCore is a unique collection of brands and products that have set the standard in meeting the demands of today’s engineers.

We reach over 15 million technologists, designers, engineers, and managers. We connect this electronics community to reliable news, authoritative analysis, industry trends, and daily information on new technology.

Our brands include EE Times, Electronic Products, EPSNews, ESM China, IoT Times, Power Electronics News, EDN, EEWeb, Electro Schematics, Elektroda.pl, Embedded.com, Planet Analog, and more.

For more information, visit https://aspencore.com.

Contact Person
Celia Shih
Marketing Manager
Taiwan/ASEAN Marketing and Circulation Department
T: +886 227591366 Ext. 103/222
E: celia.shih@aspencore.com

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/powerup-asia-2023-opens-tomorrow-with-power-electronics-trends-in-focus/

「嘉泓.環球自購」上線一周年 加推「環球團購」功能 為海外優質小眾品牌 打造亞洲營銷新渠道

EQS 新聞 via SEAPRWire.com / 2023-05-23 / 09:41 UTC+8

CN Logistics International Holdings Limited

嘉泓物流國際控股有限公司

 (於開曼群島註冊成立的有限公司)

(股份代號:2130)

 

「嘉泓.環球自購」上線一周年 加推「環球團購」功能

為海外優質小眾品牌 打造亞洲營銷新渠道

 

[香港 – 2023523] 國際知名的物流解決方案供應商 嘉泓物流國際控股有限公司(「嘉泓物流」或「本公司」,連同其附屬公司,統稱 「本集團」,股份代號:2130)欣然宣布,旗下國際集運平台「嘉泓.環球自購」加推「環球團購」功能,網羅海外優質小眾品牌,為亞洲廣大消費者提供更多品質化、個性化的商品,滿足他們高端的品味需求;同時助歐美商家拓展亞洲市場,增加品牌的知名度及市場滲透率。

 

「嘉泓.環球自購」(www.cnship4shop.com)是本集團自行研發、20225月推出的電商平台,透過結合本集團多年的物流經驗、全球網絡優勢及先進電子管理系統,為廣大消費者提供「一拍即寄」、可靠且高效的國際集運方案。現時平台覆蓋7個海外收貨點,包括美國,英國,意大利,法國,德國、丹麥和日本,以及12個亞洲目的地包括中國大陸、香港、台灣、日本、韓國、馬來西亞、印尼及泰國等。縱管過去一年受疫情的影響,平台發展步伐仍然優於預期。

 

目前,平台主要透過社交媒體進行內容營銷,主要渠道包括FacebookInstagram、領英、抖音、嗶哩嗶哩、AcFun、微博、微信、小紅書等,相關廣告已觸及逾3,000萬人次、互動次數逾750萬,網站瀏覽量逾25萬,活躍用戶數目亦以倍速攀升,達到1.2萬多人。單以今年第二季計算,平台收入較今年首季上升超過一倍,營業額表現亮麗,平均訂單價為200300歐元,顧客回頭率保持高企,印證其高端國際物流服務標準和獨特的市場定位。

 

適逢平台面世一周年,集團本月起增設「環球團購」功能,聚焦海外小眾品牌,為用戶搜羅來自時尚服飾、母嬰育兒、美容護膚和運動休閒等多個細分領域的優質產品,迎合新世代以至中產階層對於提升生活質素的需求,並藉此進一步促進平台多元化發展和創造更多收入來源。平台預計將引入百餘個海外小眾品牌,部分品牌更是首次入駐亞洲。平台日前更是與全球智慧開店平台服務的領先提供商SHOPLINE達成初步合作,透過集團在海外的強大商業網絡和供應鏈能力,為其超過 50 萬個商業用戶提供海外採購及進口服務,打造便捷可靠的跨境電商新通道,驅動亞洲零售市場,共同建立更良好的網絡營商環境。

 

 

嘉泓物流的主席兼執行董事劉石佑先生表示:「近年,電商行業發展蓬勃,不少國際品牌客戶已經投身網上市場,集團亦持續為現時品牌提供線上到線下(O2O)物流解決方案,協助其進行全方位零售,『嘉泓.環球自購』亦因此而產生。平台以『燃亮你的個性』為使命,並延續本集團聚焦高端零售市場、高增值細分領域的傳統,專注推廣及服務海外優質小眾品牌。通過國際集運方案、『環球品味』資訊分享專頁以至新增設的團購功能,助力高消費能力且年齡介乎2149歲的顧客群尋找具個人特色的產品,實現優質健康的生活態度。」

 

劉石佑先生續道:「平台成立至今,一直取得驕人的成績,絕對是本集團拓展電商領域的一大里程碑。即使疫程在今年初開始消退、大部分國家已經解除旅遊限制之下,線上零售行業和相關平台服務仍然錄得高速發展。未來『嘉泓.環球自購』會繼續乘著這股消費趨勢,探索更多發展方向,促進供給與需求的高效融合,做到亞洲高端消費者與海外小眾品牌商家的橋樑,賦予商家高效增長的空間。同時為讓消費者體驗更優質的商品,平台亦會引入更多先進零售科技提升用戶體驗,包括使用生成式人工智能、應用大數據分析、機器學習技術等,更有效地推測消費者行為,實現更精準的數位行銷;為改善服務質素和更好地控管成本,平台會升級營運系統和繼續優化用戶版面,令國際購物變得觸手可及。」

 

 

關於嘉泓物流國際控股有限公司

成立於1991年,嘉泓物流國際控股有限公司乃國際知名的物流解决方案供應商,核心業務爲提供有關時尚產品及精品葡萄酒的空運代理服務以及配送及物流服務。根據灼識諮詢報告,截至20191231日止年度,本公司在中國及香港高端時尚産品的配送及物流市場中均排名第一。欲知更多資訊,請瀏

覽嘉泓物流網站:https://www.cnlogistics.com.hk

 

文件: 「嘉泓.環球自購」上線一周年 加推「環球團購」功能 為海外優質小眾品牌 打造亞洲營銷新渠道

2023-05-23 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。

瀏覽原文: https://ift.tt/sYKyTgj

fncls.ssp?fn=show_t_gif&application_id=1638843&application_name=news&site_id=todayir_html



source https://netdace.com/eqs-newswire/%e3%80%8c%e5%98%89%e6%b3%93%ef%bc%8e%e7%92%b0%e7%90%83%e8%87%aa%e8%b3%bc%e3%80%8d%e4%b8%8a%e7%b7%9a%e4%b8%80%e5%91%a8%e5%b9%b4-%e5%8a%a0%e6%8e%a8%e3%80%8c%e7%92%b0%e7%90%83%e5%9c%98%e8%b3%bc%e3%80%8d/

Food Fortification a Major Focus at the World Health Assembly

Geneva, Switzerland, May 22, 2023 – (ACN Newswire via SEAPRWire.com) – The crucial topics of micronutrient deficiencies and Large Scale Food Fortification (LSFF) will be discussed at a side event at the 76th World Health Assembly (WHA) in Geneva on Tuesday, 23 May 2023, hosted by the governments of Colombia, Ecuador and Malaysia. At the side event, The Global Alliance for Improved Nutrition and partners will help unpack the pivotal resolution that calls on WHA Member States to scale up food fortification programs globally, particularly in countries where micronutrient deficiencies are prevalent.

The public can follow the updates on the Food Fortification resolution here.

Half of all preschool-aged children and 2/3rds of all women of reproductive age worldwide suffer from at least one micronutrient deficiency, also known as “hidden hunger”. These deficiencies cause a range of health problems, from impaired cognitive development in children to increased risk of infections and conditions such as anemia and blindness.

Lawrence Haddad, executive director of the GAIN and a speaker at the event, said, “At GAIN, we have spent the past 20 years supporting food fortification in over 40 low and middle-income countries. Unfortunately, the prevalence of malnutrition is growing globally due to simultaneous climate and food crises exacerbated by the COVID-19 pandemic and Russia’s war on Ukraine. More investment in food fortification can help to provide an important nutrition safety net as we seek to build nutritious food systems that are more resilient in the face of global shocks.”

Food fortification has been identified as a cost-effective and sustainable strategy to combat hidden hunger and improve public health. According to the WHO, fortification of staple foods can improve micronutrient status in populations and reduce the incidence of associated diseases, particularly in low- and middle-income countries where access to diverse diets and supplements is limited. Eighty-four countries could benefit from establishing new mandatory fortification programs, and most existing programs must be strengthened to reach more people with adequately fortified food.

“Food fortification is among the solutions that we are urgently pursuing to combat rising levels of malnutrition in African Union countries,” said Ambassador Josefa Sacko, Commissioner for Rural Economy and Agriculture at the African Union and member of the Scaling Up Nutrition Movement’s Lead Group. “We welcome this important resolution of the World Health Assembly as food fortification is also on the front burner at the African Union.”

The proposed WHA resolution has united the health policy, disability rights, and nutrition sectors. Over 70 global, regional, and national organizations have endorsed the resolution and are actively working to support its passage. “The World Health Organization is pleased to stand alongside Member States of the WHA and the wide coalition of stakeholders that has come together to support accelerated action on food fortification to combat micronutrient deficiency and its impacts,” said Dr. Francesco Branca, Director of the Department of Nutrition and Food Safety at WHO. “Governments need to design effective food fortification programs aimed to reach all people in need and engage civil society and the private sector for effective implementation.”

The Masters of Ceremony for the side event are Saskia Osendarp, Executive Director of the Micronutrient Forum, and Gail Rosseau, George Washington School of Medicine & Health Sciences and G4 Alliance. In addition to Lawrence Haddad, speakers will include representatives from supportive member states, food fortification experts and representatives from the disability rights, child rights, and health policy communities.

Registration for the event is open here. https://pr.report/F6yaLNnj

Contact Information:
Edwin Shankar
Media Relations
edwin.shankar@leidar.com

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/food-fortification-a-major-focus-at-the-world-health-assembly/

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

HONG KONG, May 22, 2023 – (ACN Newswire via SEAPRWire.com) – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce that an Investigational New Drug (“IND”) application for SM17 (a humanised anti-IL-17RB monoclonal antibody for injection) for the treatment of Asthma has been filed with and accepted by the Center for Drug Evaluation (“CDE”) of the National Medical Products Administration of China (“NMPA”) on 19 May. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB, which is a global first-in-class monoclonal antibody drug targeting IL17BR with the potential for treating asthma, atopic dermatitis, idiopathic pulmonary fibrosis and other immunological disorders. This IND application is mainly for the treatment of asthma, and upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese(Asian) and American(Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population.

As early as March 2022, SM17’s IND Application for the treatment of asthma was approved by the U.S. Food and Drug Administration (“FDA”), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event. We are in full steam ahead to accelerate the progress of our clinical study. According to our current progress, we expect the Phase I clinical study can be completed by the end of this year, six months ahead of the original anticipated completion date.

SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as “alarmin”, which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.

As one of the global pandemic, asthma has huge urgent and unmet medical needs, and the pharmaceutical market has a broad space. According to the Frost & Sullivan Report, the number of asthma patients worldwide is gradually increasing and expected to reach 800 million in 2024 and further increase to approximately 860 million in 2030. The number of asthma patients in China grew faster than the global growth rate and is expected to reach 70.4 million in 2024 and further increase to 78.1 million in 2030. In terms of market size, the global asthma product market is expected to reach US $38.5 billion in 2024 and US $50 billion by 2030. The asthma product market in China is expected to reach US $5.6 billion by 2024 and US $9.7 billion by 2030, of which the market size of moderate-to-severe asthma applicable for biologics will reach US $6.6 billion. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on airway inflammation and improve disease conditions. The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that, “The number of asthma patients worldwide has increased year by year, and the existing therapies have not fully met the medical needs, and there is still a huge gap in effective treatment of severe asthma. As the world’s first humanized IgG4-k monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the Company. The acceptance of IND Application for SM17 not only accelerated the Company’s clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. The Company is confident in the prospects of clinical trial and commercial development of the new drug of SM17, and will continue to explore its safety and efficacy. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients. The Company will adhere to independent innovation, continue to promote the investigatory of new drugs, expand the population of indications, spare no effort to provide more effective treatment options for Chinese and global patients, aiming to become a global leader in innovative therapies for immunological diseases.”

About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer’s disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin’s lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited
Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Cita Zhang / Ms. Willa Xue
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846
Fax: (852) 2610 0842

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/sinomab-announces-ind-application-of-sm17-for-the-treatment-of-asthma-was-accepted-by-nmpa-cde/

5/21/23

Maxity.io Announcing MAX Token Listing on MEXC Global & BitMart Exchange

London, UK, May 22, 2023 – (SEAPRWire) – Maxity.io, the world’s first Web3 social impact protocol, is proud to announce the listing of its MAX Coin on MEXC Global & BitMart Exchange at 15th May 2023 10AM UTC.

MAX Coin is the governance and utility token of Maxity that enables charities, donors, volunteers, and investors to benefit from Maxity’s ecosystem. It has a total supply of 1,000,000,000 tokens, which will be released according to MAX Coin’s vesting schedule over the period 2023 to 2026.

Maxity has integrated NFTs, MAX Forest, the Volunteer and Reward and SocialFi models, and the Symbiotic Metaverse to innovate the charity ecosystem and contribute to the United Nations’ Global Goals. By leveraging blockchain technology, Maxity aims to revolutionise the charitable industry by bringing transparency, accountability, and efficiency to the donation process. The MAX Coin is an essential part of the Symbiotic Metaverse and serves as the governance token of Maxity under the Volunteer and Reward model.

“MAX Coin has been listed today, on MEXC Global and BitMart Exchange, with prices skyrocketing by over 600% in a single day, which is exhilarating!” Professor Xiong, the Associate Vice-President for External Engagement of Surrey University and Director of Maxity, stated, “This is just the beginning. In 2023, a year marked by a complex macro-financial environment and the end of a bearish trend in the cryptocurrency industry, Maxity.io, as a representative project of Web3.0+ESG, holds great significance in its coin issuance. MAX Coin will drive Maxity to unite global philanthropists, utilising the potential of the Web3 industry and blockchain technology to address various issues in global sustainable development. The future of Maxity looks promising!”

It is reported that on May 4th, at the Creating Resilience and Sustainable Innovations Through Emerging Technologies conference held at the United Nations headquarters, Maxity.io was studied and discussed by experts as an excellent case of blockchain technology addressing the United Nations’ Sustainable Development Goals.

Maxity has currently raised funds for 138 global charitable organisations through NFTs and MAX Forest, working together with these organisations to address issues such as poverty, hunger, disability, education, gender equality, clean water, desertification, carbon emission and climate change.

The platform currently has over 200,000 users participating in philanthropic actions, with a daily active user count surpassing 30,000. It is making a positive social impact worldwide.

Maxity’s listing on MEXC Global & BitMart Exchange has gone live on 15th May 2023 and the token sale of MAX is now open to traders and investors worldwide. This is an excellent opportunity for those who share Maxity’s vision of creating a better world to get involved and make a positive impact.

To learn more about Maxity and the MAX token, please visit our website at https://maxity.io.

To buy MAX Coin, please visit: MEXCBitMart

Social Links

Twitter: https://twitter.com/maxiprotocol

Discord: https://discord.com/invite/XtMkVFacUd

Telegram: https://t.me/maxityofficial

LinkedIn: https://www.linkedin.com/company/maxity-io/

Facebook: https://www.facebook.com/profile.php?id=100076827406915

Media contact

Brand: Maxity

Contact: Media team

Website: https://maxity.io

SOURCE: Maxity

The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com

Sectors: Top Story, Daily News

SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)



source https://netdace.com/top-story/maxity-io-announcing-max-token-listing-on-mexc-global-bitmart-exchange/

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

HONG KONG, May 22, 2023 – (ACN Newswire via SEAPRWire.com) – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce that an Investigational New Drug (“IND”) application for SM17 (a humanised anti-IL-17RB monoclonal antibody for injection) for the treatment of Asthma has been filed with and accepted by the Center for Drug Evaluation (“CDE”) of the National Medical Products Administration of China (“NMPA”) on 19 May. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB, which is a global first-in-class monoclonal antibody drug targeting IL17BR with the potential for treating asthma, atopic dermatitis, idiopathic pulmonary fibrosis and other immunological disorders. This IND application is mainly for the treatment of asthma, and upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese(Asian) and American(Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population.

As early as March 2022, SM17’s IND Application for the treatment of asthma was approved by the U.S. Food and Drug Administration (“FDA”), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event. We are in full steam ahead to accelerate the progress of our clinical study. According to our current progress, we expect the Phase I clinical study can be completed by the end of this year, six months ahead of the original anticipated completion date.

SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as “alarmin”, which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.

As one of the global pandemic, asthma has huge urgent and unmet medical needs, and the pharmaceutical market has a broad space. According to the Frost & Sullivan Report, the number of asthma patients worldwide is gradually increasing and expected to reach 800 million in 2024 and further increase to approximately 860 million in 2030. The number of asthma patients in China grew faster than the global growth rate and is expected to reach 70.4 million in 2024 and further increase to 78.1 million in 2030. In terms of market size, the global asthma product market is expected to reach US $38.5 billion in 2024 and US $50 billion by 2030. The asthma product market in China is expected to reach US $5.6 billion by 2024 and US $9.7 billion by 2030, of which the market size of moderate-to-severe asthma applicable for biologics will reach US $6.6 billion. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on airway inflammation and improve disease conditions. The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that, “The number of asthma patients worldwide has increased year by year, and the existing therapies have not fully met the medical needs, and there is still a huge gap in effective treatment of severe asthma. As the world’s first humanized IgG4-k monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the Company. The acceptance of IND Application for SM17 not only accelerated the Company’s clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. The Company is confident in the prospects of clinical trial and commercial development of the new drug of SM17, and will continue to explore its safety and efficacy. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients. The Company will adhere to independent innovation, continue to promote the investigatory of new drugs, expand the population of indications, spare no effort to provide more effective treatment options for Chinese and global patients, aiming to become a global leader in innovative therapies for immunological diseases.”

About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer’s disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin’s lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited
Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Cita Zhang / Ms. Willa Xue
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846
Fax: (852) 2610 0842

Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/sinomab-annouces-ind-application-of-sm17-for-the-treatment-of-asthma-was-accepted-by-nmpa-cde/

中國抗體SM17針對治療哮喘的新藥研究申請獲國家藥監局藥品審評中心受理

HONG KONG, May 22, 2023 – (亞太商訊 via SEAPRWire.com) – 專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,SM17(注射用人源化抗IL-17RB單克隆抗體)針對治療哮喘之新藥研究申請於5月19日獲中國國家藥品監督管理局(「國家藥監局」)藥品審評中心受理。若新藥研究申請獲得批准,本公司將在中國開展治療哮喘適應症的臨床研發項目。

SM17為以白細胞介素17受體B(IL-17RB)為靶點的人源化Ig G4-k單克隆抗體,是一款全球首創針對 IL-17BR 靶點的單抗藥物,具有治療哮喘、特應性皮炎、特發性肺纖維化及其他免疫性疾病的潛力。本次新藥研究申請主要針對治療哮喘,本公司將在申請獲批後於中國啟動I期臨床試驗,以橋接中美人群並探索SM17在中國人群中的安全性。

早於2022年3月,SM17針對哮喘之新藥研究申請(IND)已獲得美國食品藥品監督管理局(FDA)批准,並於同年6月完成I期臨床試驗之首次健康受試者給藥。截至2023年5月22日,受試者均未報告嚴重不良事件。我們現正全速推進I期臨床研究。按現時進度,我們預計將於今年年底完成I期臨床研究,較原有計劃提前半年時間。

SM17通過與2型先天淋巴細胞(ILC2s)上的IL-17RB結合可抑制Th2細胞的免疫反應,從而阻止人白細胞介素25(IL-25)誘發的一連串反應。IL-25為一類關鍵的「警戒素」,已被證明與氣道細胞的病毒感染反應以及過敏性疾病如哮喘的病理變化有關。患有未受控制的嚴重哮喘的患者,會承受哮喘反復發作及住院的風險;而未受控制的嚴重哮喘疾病會引發群體死亡率及患病率升高、生活質素下降以及醫療支出增加等社會性問題。

哮喘作為全球性流行病之一,擁有廣大急切且未被滿足的醫療需求,藥品市場空間廣闊。根據弗若斯特沙利文報告顯示,全球哮喘患者的數量正在逐漸增加,預計在2024年將達到8億,並在2030年進一步增加到約8.6億。而中國的哮喘患者數量的增長速度高於全球增長率,預計在2024年將達7,040萬,並在2030年進一步增加到7,810萬。從市場規模上,預期全球哮喘產品市場於2024年將達到385億美元,於2030年前將達到500億美元。而中國哮喘產品市場將預期於2024年前將達到56億美元,於2030年前將達到97億美元,其中適合生物藥的中重度哮喘對應市場規模將達到66億美元。目前已獲批上市的嚴重哮喘療法(包括生物製劑),可一定程度降低哮喘年度發作。然而,嚴重哮喘的有效治療仍存在未滿足的醫療需求,尤其是對當前療法無應答的患者而言。本公司相信靶向Th2炎性細胞因數通路的上游(例如IL -17RB)的療法,預計將對氣道炎症相關的病理變化產生廣譜的作用並改善疾病病情,相信SM17或擁有巨大潛力以緩解未被滿足之哮喘治療需求。

中國抗體製藥有限公司執行董事、主席兼首席執行官梁瑞安博士表示:「全球哮喘患者數量的逐年增加,而目前已有的哮喘療法尚未完全滿足患者的醫療需求,嚴重哮喘的有效治療仍存在巨大缺口。SM17作為一款全球首創針對IL-17RB靶點的人源化IgG4-k單克隆抗體,在本公司積極推進下,臨床研究進展理想。此次SM17新藥研究申請獲得受理,不僅加快推進本公司在中國開展治療哮喘適應症的臨床研發項目,亦體現了我們新藥研發的效率之高。本公司對SM17新藥巨大的臨床試驗及商業化開發前景充滿信心,將繼續致力於探索其安全性和有效性,並期待該治療新選擇未來可以惠及更多中國患者,為嚴重哮喘患者群體帶來治療的曙光。本公司將繼續堅持自主創新,持續推進新藥研究工作,不斷拓展適應症人群,不遺餘力地為中國和全球患者提供更多有效的治療選擇,旨在成為免疫疾病創新療法的全球領先者。」

關於中國抗體製藥有限公司
中國抗體製藥有限公司專注於研究、發展、製造及商業化免疫性疾病療法,研發總部位於香港、生產基地位於中國。公司注重科技研發,其旗艦產品SM03舒西利單抗(Suciraslimab)為全球首項用以治療類風濕關節炎的CD22單抗,已在中國完成類風濕關節炎三期臨床試驗,並被列為國家十三五重大新藥創制專項重大項目。此外還有多個同類靶點首創(First-in-target)及同類首創(First-in-class)在研藥物,部分已處於臨床階段,適應症覆蓋類風濕關節炎、阿茲海默症、系統性紅斑狼瘡、天皰瘡、多發性硬化症、視神經脊髓炎譜系疾病、非霍奇金氏淋巴瘤、哮喘等具有重大未滿足臨床需求的疾病。

此新聞稿由金融公關(香港)有限公司代表中國抗體製藥有限公司發佈。如有垂詢,請聯絡:
金融公關(香港)有限公司
趙泳絲小姐/張曉茵小姐/張曉敏小姐 / 薛偉靜小姐
電郵:sinomab@financialpr.hk
電話:(852)2610 0846
傳真: (852)2610 0842

Copyright 2023 亞太商訊. All rights reserved. (via SEAPRWire)



source https://netdace.com/acn-newswire/%e4%b8%ad%e5%9c%8b%e6%8a%97%e9%ab%94sm17%e9%87%9d%e5%b0%8d%e6%b2%bb%e7%99%82%e5%93%ae%e5%96%98%e7%9a%84%e6%96%b0%e8%97%a5%e7%a0%94%e7%a9%b6%e7%94%b3%e8%ab%8b%e7%8d%b2%e5%9c%8b%e5%ae%b6%e8%97%a5/

Armed attack leaves 10 rally drivers dead in Mexico car race

In this phioto dated Jan 5, 2007, Mexican Navy officers check motorists using the highway between Tijuana and Ensenada city, in Baja California state, border with US, as part of the operative against organized crime. (PHOTO / AFP)

MEXICO CITY – At least ten people were killed and nine others injured in an armed attack targeting a group of amateur rally drivers in a car race in the Mexican state of Baja California on Saturday, local media reported.

A group of armed individuals got out of a vehicle and opened fire at the car race participants who were parked on the side of a highway in Ensenada, Baja California, said the Milenio newspaper citing local authorities.

The attack "left nine wounded and 10 people dead," Ensenada authorities said in a statement.

ALSO READ: Mexico urges US to tackle gun violence on border

The authorities are now conducting an investigation.



source https://netdace.com/latest-news/armed-attack-leaves-10-rally-drivers-dead-in-mexico-car-race/

UN appeals funding to help people fleeing Sudan to Ethiopia

Refugees from Sudan who crossed into Ethiopia wait for the bus in Metema, Ethiopia on May 5, 2023. (PHOTO / AFP)

ADDIS ABABA – The United Nations Office for the Coordination of Humanitarian Affairs appealed for additional funding to address the needs of people crossing into Ethiopia due to the ongoing security situation in Sudan.

The UNOCHA, in its latest situation update issued Friday, said some 85,0000 people are projected to enter Ethiopia from Sudan, with humanitarian needs forecasted to rise steeply in such a scenario.

"Additional financial resources are required to meet the current needs and the ongoing flow of arrivals expected in the weeks ahead," it said.

Figures from the UNOCHA show that between April 21 and May 16, more than 22,600 arrivals have been recorded from more than 64 nationalities at Metema crossing point in Ethiopia's northwest Amhara region

Figures from the UNOCHA show that between April 21 and May 16, more than 22,600 arrivals have been recorded from more than 64 nationalities at Metema crossing point in Ethiopia's northwest Amhara region. Metema crossing point is now receiving the largest share of people fleeing conflict in Sudan.

According to the UNOCHA, arrivals have been observed to have largely come from the city of Khartoum, the Sudanese capital, representing 76 percent of the total arrivals. Some 18 percent of them are said to be from the city of Omdurman.

ALSO READ: Khartoum under bombardment as Sudan's rivals talk

On Wednesday, the International Organization for Migration had launched a response plan appealing for $209 million to provide humanitarian assistance to the people affected by the crisis and outbreak of violence in Sudan.

The UN migration agency said the deteriorating situation in Sudan is also having dramatic implications on neighboring countries, many of which are grappling with their own protracted crises.

READ MORE: Violent clashes in Ethiopia's Amhara as unrest deepens

Sudan has witnessed deadly armed clashes between the Sudanese Armed Forces and the paramilitary Rapid Support Forces in the capital city of Khartoum and other areas since April 15, with the two sides accusing each other of initiating the conflict. 



source https://netdace.com/latest-news/un-appeals-funding-to-help-people-fleeing-sudan-to-ethiopia/

5/20/23

Greeks living abroad vote in general elections

Supporters of Greek Prime Minister and leader of the conservative New Democracy party, wave the party's flags during his main campaign rally in Thessaloniki on May 18, 2023, ahead of Greece's general elections. (PHOTO / AFP)

ATHENS – Greeks living abroad started casting their ballots for the general elections on Saturday, a day earlier than voters living in Greece.

It is the first time ever that Greek expatriates can vote from their place of residence, based on criteria set out in a recent law.

In previous elections, Greek expatriates who wanted to participate in elections had to return to Greece to vote.

All recent opinion polls indicate that the ruling conservative New Democracy (ND) party leads, with the Leftists following second and the Socialists third

A total of 22,816 expatriates registered to vote in places where they are living, according to the Interior Ministry. They can vote at 99 polling centers located in 35 countries, as a minimum of 50 registered in an area was required to set up a polling station.

ALSO READ: Greece's top court bans far-right party from general elections

Most have registered in the United Kingdom, Germany, the United States, Belgium and Cyprus, according to the ministry.

Their ballots will be sent back in sealed bags by planes and the votes will be sorted when the polls close in Greek territory, Greek national news agency AMNA reported.

A total of 9.8 million Greeks are eligible to elect the 300 members of parliament.

All recent opinion polls indicate that the ruling conservative New Democracy (ND) party leads, with the Leftists following second and the Socialists third.

According to political analysts, due to the way the Greek electoral system works, it will be difficult for any single political party to secure a clear parliamentary majority in the first round.

READ MORE: PM: Greece to hold national election on May 21

If a second election round is required, it will take place at the beginning of July at the latest, the government has said. The second round would be held under new electoral rules, which provide for extra seats for the winning party.



source https://netdace.com/latest-news/greeks-living-abroad-vote-in-general-elections/

Montenegro’s new president takes oath of office

Montenegro's president-elect Jakov Milatovic (center), his wife Milena and outgoing President Milo Djukanovic (right), attend his inauguration ceremony in Podgorica on May 20, 2023. (PHOTO / AFP)

BELGRADE – The newly elected president of Montenegro Jakov Milatovic took the oath of office on Saturday at the country's parliament in Podgorica.

Milatovic said that he will serve as the president of all citizens, emphasizing economic development and ties with the neighboring countries, as well as the country's path to full membership in the European Union (EU).

"The elimination of internal divisions, the building of strong and independent institutions, the affirmation of human rights, the impartial distribution of justice, a society of equal opportunities, as well as the establishment of a sustainable economic model will require the full commitment of both decision-makers and those who execute those decisions," he said in a speech, which was broadcast live on the national television RTCG.

ALSO READ: Xi congratulates new Montenegrin president Milatovic

Milatovic won the April presidential election in the second round, in which he won nearly 60 percent of the vote, while former president Milo Djukanovic gathered 40 percent.



source https://netdace.com/latest-news/montenegros-new-president-takes-oath-of-office/

Canada announces new sanctions against Russia

Canada's Prime Minister Justin Trudeau attends a meeting during the G7 Leaders' Summit in Hiroshima, western Japan on May 19, 2023. On the same day, Canada announced new sanctions against Russia. (PHOTO / AP)

OTTAWA – Canada announced new sanctions against Russia on Friday.

According to a news release on the prime minister's website, Canada is imposing new sanctions on 17 individuals and 18 entities linked to Russian companies that provide military technology and know-how to Russia's armed forces, family members of listed persons, and members of the Kremlin elite.

ALSO READ: Hungarian chief diplomat calls Western sanctions 'complete failure'

The news release said other sanctions on 30 individuals and 8 entities are involved in human rights violations.

Since 2014, Canada has imposed sanctions on more than 2,500 individuals and entities in Russia, Belarus, and Ukraine. Many of these sanctions have been undertaken in coordination with Canada's allies and partners.



source https://netdace.com/latest-news/canada-announces-new-sanctions-against-russia/